Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Graft-versus-host disease (GvHD) is a common and potentially serious complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT).
HSCT is used as a potential cure for hematological cancers, syndromes of bone marrow failure, and congenital disorders of the hematopoietic system (Hymes, Alousi and Cowen, 2012; Passweg et al., 2025). GvHD occurs when the donor stem cells or the graft attack healthy cells in the patient or the host (Blood Cancer United, 2024). GvHD can damage a patient’s tissues and organs, skin, eyes, mouth, hair, nails, liver, esophagus, intestines, joints, lungs, and genitals (Blood Cancer United, 2024). There are two main types of GvHD: acute GVHD (aGvHD), and chronic GvHD (cGvHD).
In the 7MM, the number of diagnosed incident cases of first allogeneic HSCT is expected to increase by 13.91% over the forecast period at an annual growth rate (AGR) of 1.39% from 23,192 cases in 2025 to 26,418 cases in 2035. In 2035, the US will have the highest number of diagnosed incident cases of first allogenic HSCT in the 7MM with 11,087 cases, and France will have the fewest diagnosed incident cases of first allogenic HSCT with 1,590 cases. In the 7MM, the number of three-year diagnosed prevalent cases of aGvHD is expected to increase by 15.87% over the forecast period at an AGR of 1.59%, from 21,968 cases in 2025 to 25,454 cases by 2035. In 2035, the US will have the highest number of three-year diagnosed prevalent cases of aGvHD in the 7MM with 11,670 cases, and France will have the fewest three-year diagnosed prevalent cases of aGvHD with 1,494 cases. In the 7MM, the number of three-year diagnosed prevalent cases of cGvHD is expected to increase by 15.91% over the forecast period at an AGR of 1.59%, from 25,768 cases in 2025 to 29,867 cases by 2035. In 2035, the US will have the highest number of three-year diagnosed prevalent cases of cGvHD in the 7MM with 13,824 cases, and France will have the fewest three-year diagnosed prevalent cases of cGvHD with 1,769 cases. GlobalData epidemiologists attribute the increase in diagnosed incident and three-year diagnosed prevalent cases of aGvHD and cGvHD partly to the moderately rising trend of increase in transplantation in the 7MM.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for GvHD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of first allogeneic HSCT, diagnosed incident cases of aGvHD, and diagnosed incident cases of cGvHD. The diagnosed incident cases of aGvHD and cGvHD are segmented by overall age (0–18 years and above 18 years), donor types, and three-year diagnosed prevalent cases. The diagnosed incident cases of aGvHD are further segmented by Glucksberg severity grades, and 100-day mortality. The diagnosed incident cases of cGvHD are further segmented by severity based on National Institutes of Health (NIH), and one-year mortality. This report focuses on aGvHD segmented by severity, defined by the Mount Sinai Acute GvHD International Consortium (MAGIC), and cGvHD segmented by severity by NIH. This definition is applied consistently across all markets. This epidemiology forecast for GvHD is supported by data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident cases of first allogeneic HSCT, aGvHD, and cGvHD across these markets.

Reasons to Buy

The Graft-versus-host disease (GvHD) epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global GvHD market.

Quantify patient populations in the global GvHD market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for GvHD therapeutics in each of the markets covered.

Table of Contents

Executive Summary

Disease Overview

Epidemiological Forecast

Sources and Methodology

Discussion

Appendix

Contact Us

Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
IDWeek 2026: Conference Highlights
$3,750 | November 2026
Pharmaceuticals
New
CRO Activity and Intel Report Q3 2026
$1,870 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035 in real time.

  • Access a live Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.